Publication at First Faculty of Medicine |
2016
Abstract
Alemtuzumab is a humanized monoclonal antibody approved for the therapy of highly active relapsing-remitting multiple sclerosis. It binds to the superficial antigen CD52 on circulating B- and T-lymphocytes and causes their cytolysis.
Developing new lymphocyte repopulations result in subsequent suppression of inflammatory activity. Phase II and III clinical studies including an active comparator (IFN-β1a) showed higher efficacy of alemtuzumab, and data from clinical trial extensions confirm its long-term effect.
Conducted studies revealed consistent safety profile while other follow-ups did not find any data suggesting its change.